 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...3233343536373839404142...6263» |
- | Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Journal: The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes. (Pubmed Central) - Apr 29, 2021
These INSTIs induced adipogenesis, lipogenesis, oxidative stress, fibrosis, and insulin resistance. The present study is the first to shed light on the fat modifications observed in INSTI-treated HIV-infected individuals.
- || bictegravir (GS-9883) / Gilead
Clinical, Journal: Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. (Pubmed Central) - Apr 28, 2021
Weight gain is ubiquitous in clinical trials of ART initiation, and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens contributing. The mechanisms by which certain ART agents differentially contribute to weight gain are unknown.
- || Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Clinical, Journal: Food insecurity is associated with lower levels of antiretroviral drug concentrations in hair among a cohort of women living with HIV in the United States. (Pubmed Central) - Apr 28, 2021
Food insecurity was associated with lower ART concentrations in hair, suggesting that food insecurity may be associated with sub-optimal ART adherence and/or drug absorption. Interventions that aim to improve ART adherence among WLHIV should consider and address the role of food insecurity.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. (Pubmed Central) - Apr 28, 2021
Yearly weight gain increased following switch to INSTI, particularly for women, blacks and persons age ≥60. Concomitant increases in waist circumference suggest that this weight gain is associated with an increase in fat mass.
- | Journal: Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. (Pubmed Central) - Apr 28, 2021
In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared to dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Dolutegravir is not associated with weight gain in ART experienced geriatric patients living with HIV. (Pubmed Central) - Apr 28, 2021
Results from a large Italian cohort did not show a significant WG associated with switch to DTG in PLWH 65 years of age or older. This finding emerged also when comparing 3DR vs 2DR and TAF exposed and unexposed geriatric PLWH.
- |||||| Tivicay (dolutegravir) / ViiV Healthcare
New trial: BMS02: Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana (clinicaltrials.gov) - Apr 27, 2021
P, N=200, Not yet recruiting, Sponsor: Duke University
- || bictegravir (GS-9883) / Gilead
Clinical, Journal: Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals. (Pubmed Central) - Apr 24, 2021
The transmission of strains with integrase antiretroviral resistance has been previously documented in treatment naïve patients. Given the increase of patients treated with integrase inhibitors, surveillance of drug resistance mutations is an essential aspect of PR's clinical management of HIV infection.
- || Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
New P1 trial: A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants (clinicaltrials.gov) - Apr 23, 2021
P1, N=36, Not yet recruiting, Sponsor: ViiV Healthcare
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Observational data, Journal: Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: Prevalence and associated factors. (Pubmed Central) - Apr 21, 2021
Age (adjusted odds ratio [OR] 1.07; 95% CI 1.04-1.11), female sex (OR 3.02; 95% CI 1.55-5.91), VF (OR 1.98; 95% CI 1.01-3.87), dolutegravir (DTG)-based regimen (OR 2.10; 95% CI 1.05-4.20), hip-circumference (OR 1.03; 95% CI 1.01-1.05), T-lymphocyte count (OR 2.23; 95% CI 1.44-3.43), high-sensitivity C-reactive protein (hsCRP) (OR 1.14; 95% CI 1.01-1.29), and fasting insulin (OR 1.02; 95% CI 1.01-1.04) were significantly associated with MetS.Metabolic syndrome was highly prevalent among HIV+ adults receiving ART in Zambia and associated with demographic, clinical, anthropometric, and inflammatory characteristics. The association between MetS and dolutegravir requires further investigation, as does elucidation of the impact of MetS on ART outcomes in sub-Saharan African PWH.
- || bictegravir (GS-9883) / Gilead
Clinical, Journal: Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients failing an INSTI-based regimen. (Pubmed Central) - Apr 20, 2021
The aim of this study was to characterize the genotypic and phenotypic resistance profile to the integrase strand transfer inhibitor (INSTI) bictegravir (BIC) and other INSTIs in patients who previously failed twice-daily raltegravir (RAL)-based or twice-daily dolutegravir (DTG)-based regimens...Of these 14 samples, all showed high levels of resistance to elvitegravir (EVG) and RAL...Overall, for the 14 INSTI-resistant isolates, the median (range) fold-change in phenotypic susceptibility was: BIC 3.2 (0.6, 66), DTG 6.3 (0.8, >186), EVG >164 (2.6, >164), and RAL >188 (2.7, >197). In conclusion, our findings supported the in vitro activity of BIC and DTG against most isolates derived from highly treatment-experienced patients failing INSTI regimens.
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: Letter to the editor in re: Mohan et al., 2020 'dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels'. (Pubmed Central) - Apr 19, 2021
In conclusion, our findings supported the in vitro activity of BIC and DTG against most isolates derived from highly treatment-experienced patients failing INSTI regimens. No abstract available
- || Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Tivicay (dolutegravir) / ViiV Healthcare
I am not sure whether or not we reached and consensus but it seems that if it was working, you don't have to change it, maybe the exception is rilpivirine with dolutegravir alone? (Twitter) - Apr 18, 2021
- || You could use Juluca I guess, emtricitabine mostly used 3 drug combination like biktarvy, or descovy plus tivicay. Sorry, some times I am too lazy for the names and abbreviations (Twitter) - Apr 18, 2021
- | Tivicay (dolutegravir) / ViiV Healthcare
Preclinical, Journal: In response to the Letter to the Editor by Romach et al. re our publication "Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels". (Pubmed Central) - Apr 18, 2021
No abstract available No abstract available
- | grazoprevir (MK-5172) / Merck (MSD), Daklinza (daclatasvir) / BMS
Journal: Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach. (Pubmed Central) - Apr 16, 2021
In the current investigation, simeprevir was identified as the potential antiviral drug based on the in silico findings in comparison to remdesivir, favipiravir and other 53 drugs. Further, laboratory and clinical investigations are needed to be carried out which will aid in the development of quick therapeutics designed for COVID-19.
- || Tivicay (dolutegravir) / ViiV Healthcare
Sounds that this will be like the dolutegravir NTD issue. People will have to decide. Easy to talk if we’re not the affected group. In order to earn people’s trust we have to show we care. Halting and assessing to me sounds the right thing to do for now. (Twitter) - Apr 14, 2021
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] Real-World DATA Analysis of Antiretroviral Treatment for HIV-Infected Adult Patients in Ukraine () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_708;
CONCLUSIONS. ABC/VEN analysis of the real-world data showed that medicines for the antiretroviral treatment for adult HIV-infected patients in Ukraine correspond to the international treatment guidelines and regulatory lists which provides reliable additional evidence for the health technology assessment.
- ritonavir / Generic mfg.
[VIRTUAL] Pharmacoeconomic Analysis of Antiretroviral Therapy (ART) Based on Local D?ta from Real Clinical Practice, and Modeling Changes in Approaches to the HIV Treatment in the Russian Federation () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_646;
The introduction of routine genotyping for a personalized approach to the selection of ART regimen allows to reduce the cost of managing HIV-infected patients due to a decrease in the number of therapy changes. The increased use of dolutegravir in the first line of HIV therapy increases the cost of ART up to 10%.
- ||| bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Clinical: Dolutegravir + metformin. Supposed to require less metformin. Even with same dose of metformin I had so many patients loose glycemic control with this combo I won't prescribe dolutegravir to diabetics anymore. Having better success with Bictegravir. (Twitter) - Apr 11, 2021
- || Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir + metformin, cobi + steroids, INSTIs and divalent cations, rifamycins + dtg/bic.. (Twitter) - Apr 11, 2021
- | Trial completion: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Apr 8, 2021
P2, N=84, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The increased use of dolutegravir in the first line of HIV therapy increases the cost of ART up to 10%. Active, not recruiting --> Completed
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (clinicaltrials.gov) - Apr 8, 2021
P3, N=244, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Tivicay (dolutegravir) / ViiV Healthcare
Mostly RCT data free area. Intrinsic R to NNRTIs and Enfurvitide, viral load monitoring is a real challenge, starting with Dolutegravir +2NRTIs recommended for treatment initiation in co-infection. Learned from the best @Armstrws (Twitter) - Apr 7, 2021
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms among Integrase strand transfer Inhibitor-Naïve HIV-1 Patients from Cameroon. (Pubmed Central) - Apr 7, 2021
We identified major RAMs to INSTIs, which might have a potential clinical impact to dolutegravir (DTG) roll out in resource-limited settings (RLS) including Cameroon. This is the first study to describe RAMs among INSTI naïve people living with HIV-1 (PLHIV-1) infected with CRF02_AG and other subtypes in Cameroon.
- || rifampicin / Generic mfg.
PK/PD data, Retrospective data, Journal: Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis. (Pubmed Central) - Apr 7, 2021
Nevirapine- or dolutegravir-based ART and malaria or HIV infection were not associated with significant effects...The risk of achieving sub-therapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampicin respectively.
- || Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
Clinical, Journal: Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy. (Pubmed Central) - Apr 7, 2021
An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampicin respectively. We found a non-significant trend for an association between exposure to raltegravir at conception and birth defects which needs to be evaluated by larger prospective surveillance data, as these drugs are increasingly prescribed in women living with HIV.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Unexpected interactions between dolutegravir and folate: randomised trial evidence from South Africa. (Pubmed Central) - Apr 7, 2021
Unexpectedly, no declines were noted in the dolutegravir-containing arms, and concentrations were considerably higher than in the efavirenz arm. The possibility that dolutegravir may block cellular uptake of folate warrants investigation.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis. (Pubmed Central) - Apr 7, 2021
Atazanavir and Dolutegravir impair osteogenesis. It is essential to diagnose impaired osteogenesis early and to devise effective therapeutic interventions to preserve bone health in ART-treated HIV patients, putting it in the context of a correct antiretroviral combination.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal, HEOR: Addressing Pediatric HIV Pretreatment Drug Resistance and Virologic Failure in Sub-Saharan Africa: A Cost-Effectiveness Analysis of Diagnostic-Based Strategies in Children ≥3 Years Old. (Pubmed Central) - Apr 7, 2021
We evaluated the cost-effectiveness of diagnostic-based strategies (improved switching and PDR testing), over a 10-year time horizon, in settings without and with pediatric dolutegravir (DTG) availability as first-line ART...Even when substantial financial investment is needed to achieve improved regimen switching practices, the improved switching strategy still has the potential to be cost-effective in a wide range of sub-Saharan African countries. Our analysis highlights the importance of strengthening existing laboratory monitoring systems to improve the health of children living with HIV.
- | Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir Plus TAF Associated With Steepest Weight Gain @HeatherBoerner https://t.co/ecwoSusWLh #CROI2021 (Twitter) - Mar 30, 2021
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance. (Pubmed Central) - Mar 27, 2021
Participants with baseline NRTI resistance, much of which was previously undocumented, maintained suppression 48 weeks after switching to B/F/TAF or DTG+F/TAF triple therapy. Blips and virologic failure were uncommon using either regimen, with no treatment-emergent resistance.
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Second-line Switch to Dolutegravir Study (clinicaltrials.gov) - Mar 26, 2021
P4, N=795, Active, not recruiting, Sponsor: University of Nairobi
Blips and virologic failure were uncommon using either regimen, with no treatment-emergent resistance. Recruiting --> Active, not recruiting
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Head-to-Head: Evidence Mounts for Dolutegravir Superiority in Children https://t.co/TkY0QX9Vip #HIV #CROI2021 (Twitter) - Mar 24, 2021
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Weight gain and integrase inhibitors. (Pubmed Central) - Mar 24, 2021
Although INSTI-based regimens are highly efficacious for viral suppression, they appear to cause more weight gain and treatment emergent obesity than non-INSTI-based regimens and may increase the risk of weight-related comorbidities. More studies are needed to understand the pathogenesis of weight gain with INSTIs in PLWH, in order to prevent this serious complication.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Two drugs regimens for HIV. (Pubmed Central) - Mar 24, 2021
More studies are needed to understand the pathogenesis of weight gain with INSTIs in PLWH, in order to prevent this serious complication. 2DR will increasingly form part of the choice we are able to offer people with HIV but we must consider some of the limitations to ensure these regimens are used in the most clinically appropriate manner.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection. (Pubmed Central) - Mar 23, 2021
More than half of treatment-experienced children, adolescents and young adults with detectable viremia at INSTI initiation did not achieve VS, while half of those with prior VS experienced transient viremia. Further evaluation of long-term outcomes associated with INSTI use among children, adolescents and young adults is warranted.
- || bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Review, Journal: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. (Pubmed Central) - Mar 23, 2021
Further evaluation of long-term outcomes associated with INSTI use among children, adolescents and young adults is warranted. Un-boosted integrase inhibitors had better efficacy and similar safety compared to PI/rs at W96 in treatment-naïve patients with HIV-1, with DTG being among the most efficacious core agent, particularly in patients with baseline VL > 100,000 copies/mL or ≤ 200 CD4 cells/μL, who can be difficult to treat.
- ||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed (clinicaltrials.gov) - Mar 22, 2021
P3, N=567, Completed, Sponsor: Gilead Sciences
Un-boosted integrase inhibitors had better efficacy and similar safety compared to PI/rs at W96 in treatment-naïve patients with HIV-1, with DTG being among the most efficacious core agent, particularly in patients with baseline VL > 100,000 copies/mL or ≤ 200 CD4 cells/μL, who can be difficult to treat. Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. (Pubmed Central) - Mar 19, 2021
Active, not recruiting --> Completed Our data demonstrate that individuals with HBV monoinfection may be disadvantaged compared to those with HIV coinfection, highlighting potential systematic inequities in referral, monitoring and treatment.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] COVERAGE OF VIRAL LOAD MONITORING DURING PREGNANCY IN SOUTH AFRICA, NATIONAL SURVEY () - Mar 18, 2021 - Abstract #CROI2021CROI_953;
The low viral suppression among pregnant women initiating ART during pregnancy highlights the importance of enhanced adherence counselling and the need to fast-track the roll-out of Dolutegravir to enable achievement of more rapid viral suppression. The coverage of viral load testing could be improved further by implementing quality improvement initiatives.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] WOMEN ARE LESS LIKELY TO RECEIVE DOLUTEGRAVIR-BASED FIRST-LINE ART IN SOUTH AFRICA () - Mar 18, 2021 - Abstract #CROI2021CROI_950;
In South African clinics, women were less likely to receive DTG than men. Efforts to improve DTG uptake among women should be strengthened, especially as recent evidence suggests lower risks from conceiving on DTG than originally feared.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] CHANGES IN ACCESS TO CARE FOR WOMEN LIVING WITH HIV DURING THE COVID-19 PANDEMIC () - Mar 18, 2021 - Abstract #CROI2021CROI_939;
Addressing medication stock-outs and transportation challenges may help HIV programs in resource-constrained settings ensure that access to HIV and FP services is not disrupted during the COVID-19 pandemic. As the pandemic continues, FP access and use should continue to be monitored to avoid unintended pregnancies.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] OPTIMIZING DOLUTEGRAVIR INITIATION IN NEONATES USING POPULATION PHARMACOKINETIC MODEL () - Mar 18, 2021 - Abstract #CROI2021CROI_817;
Initiating infant DTG at 24-48 hrs after birth is appropriate when the last maternal dose was given within 24 hours of delivery. PopPK modeling and simulation can help evaluate neonatal DTG concentrations and dosing regimens to guide future clinical trials.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] DOLUTEGRAVIR AND VIRAL LOAD SUPPRESSION AMONG PEDIATRIC PATIENTS IN CARE IN ZAMBIA () - Mar 18, 2021 - Abstract #CROI2021CROI_810;
DTG-associated regimens were associated with superior viral suppression among children living with HIV in Zambia, supporting their inclusion in the national guidelines for all eligible pediatric clients.The lack of an objective ART adherence tool is a limitation of this study. Improved fidelity of DTG-containing pediatric ART regimens are likely to attain sustained viral suppression and improved health outcomes.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] LOWER INSULIN SENSITIVITY EARLY IN LIFE WITH IN UTERO HIV/ART EXPOSURE IN BOTSWANA () - Mar 18, 2021 - Abstract #CROI2021CROI_800;
In this cohort, newborns HEU had lower insulin sensitivity compared to those HUU from birth to 1 mo. Future studies to evaluate the longterm significance of this early life metabolic alteration are warranted.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] THE RISK OF GESTATIONAL HYPERTENSION WITH USE OF DOLUTEGRAVIR AT CONCEPTION () - Mar 18, 2021 - Abstract #CROI2021CROI_786;
Gestational HTN is more common among women on DTG at conception than women on EFV at conception, but less common than in WWoH. Further research is needed to determine if this is related to maternal weight.
- dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan, Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL () - Mar 18, 2021 - Abstract #CROI2021CROI_782;
There are consistent associations between pre-pregnancy clinical obesity and higher risks of adverse maternal, infant and child health outcomes. For every 100 women becoming pregnant after three years of TAF/FTC+DTG treatment, this analysis predicted 18 additional adverse outcomes.
- Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
[VIRTUAL] MATERNAL WEIGHT AND ADVERSE PREGNANCY OUTCOMES AMONG WOMEN ON ART AT CONCEPTION () - Mar 18, 2021 - Abstract #CROI2021CROI_781;
ART regimens associated with weight gain may reduce the percentage of low weight women at risk for certain severe adverse pregnancy outcomes but increase the number at risk of maternal hypertension. Further research is needed to determine whether weight-based ART treatment strategies could improve maternal and child health.
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] HYPERGLYCEMIA AND DIABETES MELLITUS IN PERSONS LIVING WITH AND WITHOUT HIV IN AFRICOS () - Mar 18, 2021 - Abstract #CROI2021CROI_729;
In this African cohort, hyperglycemia and diabetes were more commonly seen in PLWH than persons without HIV especially those over 50. There was a higher incidence of hyperglycemia in the PLWH 50 did not pose a significant risk for incident diabetes although this is likely limited by the sample size.